AC
GRNA

Aristeia Capital’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Aristeia Capital’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-644,916
Closed -$6.4M – 828
2021
Q4 		$6.4M Hold
644,916
– – 0.11% 226
2021
Q3 		$6.38M Hold
644,916
– – 0.12% 220
2021
Q2 		$6.33M Buy
+644,916
New +$6.29M 0.13% 217

Other funds holding GRNA

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
VS
VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return
CGC
Continental Grain Company New York $448M AUM 6.81% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCMH
Oxbow Capital Management (HK) Hong Kong $355M AUM 567.47% 1-Year Est. Return

Aristeia Capital's GRNA Position: Q1 2022 in Review

Aristeia Capital sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2022, closing a stake of 644,916 shares — an estimated $6.4M sold.

Aristeia Capital first reported a position in GRNA in Q2 2021 and held it in 3 quarters. The position peaked at $6.4M in Q4 2021. 39 funds tracked by Wall St. Rank hold GRNA as of Q1 2022.

  • Aristeia Capital reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2022 after selling out during the quarter.
  • Aristeia Capital sold 644,916 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2022, an estimated $6.4M.
  • Aristeia Capital first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2021 and held it in 3 quarters.
  • Aristeia Capital's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $6.4M in Q4 2021.
  • 39 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2022.

Based on Aristeia Capital's 13F filing for Q1 2022, filed 16 May 2022.